Cancer is an important disease in dogs and represents one of the major causes of canine death accounting for 27% of all deaths in purebred dogs in the UK in a recent mortality study. It is hard to know whether cancer in dogs is actually increasing. If it is, an increase in the diagnosis of cancer in dogs could be the result of improvements in health and welfare, which means that animals are living longer, and cancer is generally a disease of older age. Advances in veterinary medicine, particularly diagnostics and higher expectations of the pet owning public, are likely to result in an increased rate of diagnosis.

Similar to humans, many different types of naturally occurring cancer may affect dogs. Dogs live in our environment and eat similar food, and are thus exposed to similar risk.

Canine cutaneous histiocytoma is one of the most common tumour types, followed by lipoma, adenoma, soft tissue sarcoma, mast cell tumour, osteosarcoma and lymphoma.

The increased rate of diagnosis of cancer in pets, and the increasing number of owners who want to create the best possible outcome for their pet, has driven the development of Ocoxin, a nutraceutical to help support patients during their treatments.

Ocoxin is high in activated antioxidants, and has been designed to help maintain a better quality of life for cancer patients, before, during & after treatment.

Until now, pet owners have had limited options to treat their pets when cancer has been diagnosed. Chemotherapy, pain relief and surgery are amongst common options currently offered. Ocoxin offers an additional positive step for nutritionally supporting their pet.

The main ingredients in Ocoxin are green tea extracts and other powerful antioxidants.

Ocoxin is easy for pet owners to give, as it’s a palatable oral solution.

Mast cell tumour